Healthcare Leader John R. Palumbo Joins Lucid Diagnostics Board of Directors

Lucid Diagnostics Welcomes John R. Palumbo to Board

Lucid Diagnostics Inc., a noteworthy player in cancer prevention medical diagnostics, has made a significant strategic move by appointing John R. Palumbo to its Board of Directors, effective September 22, 2025. This appointment signals the company's commitment to strengthening its leadership as it navigates through crucial developmental phases.

John R. Palumbo is not just any executive; he brings with him a wealth of experience gathered over a 40-year career in the healthcare sector. His impressive resume showcases his proficiency in guiding both early-stage ventures and established Fortune 100 companies toward commercial success. Lishan Aklog, M.D., the Chairman and CEO of Lucid, commended Palumbo’s experience, stating that his insights and vast network will be invaluable as Lucid approaches key growth milestones.

Palumbo expressed enthusiasm about joining Lucid during this pivotal stage. He highlighted the importance of the company's mission, which focuses on addressing significant unmet needs in cancer prevention, particularly through its innovative product, EsoGuard. This breakthrough aims to offer preventative measures for patients at risk of esophageal cancer, showcasing the company’s dedication to improving cancer outcomes.

Throughout his career, Palumbo has successfully launched multiple companies via Initial Public Offerings (IPOs) and has facilitated significant transformations within large organizations. His recent role as Executive Chairman of ValueHealth demonstrated his capability in leading complex recapitalizations and strategic investments.

Prior to this, Palumbo held notable positions at AmerisourceBergen Corporation, where he greatly expanded their Provider business unit into a comprehensive multibillion-dollar platform serving health systems across the country. He also served as Chief Operating Officer at Allscripts Healthcare Solutions, playing a crucial role in the company’s evolution into one of the leading electronic medical record platforms.

Palumbo's career began at Shared Medical Systems, where he was pivotal in leading National Health Services before its acquisition by Siemens Healthineers. Over the past fifteen years, he has continued to contribute substantially as a board chairman and senior advisor to numerous healthcare technology and services companies.

His appointment to Lucid is expected to catalyze the company’s strategic direction significantly. The EsoGuard® Esophageal DNA Test, paired with the EsoCheck® Esophageal Cell Collection Device, represents a groundbreaking advancement in noninvasive procedures aimed at the early detection of esophageal precancer. This approach exemplifies Lucid’s mission to tackle the escalating issue of esophageal cancer linked with gastroesophageal reflux disease (GERD).

In conclusion, John R. Palumbo's extensive expertise and leadership experience are set to enhance Lucid's trajectory as it works to innovate in cancer prevention. As Lucid prepares for transformative commercial milestones, the addition of a seasoned executive like Palumbo to its Board could well be a game-changer in the fight against cancer.

For more updates on Lucid Diagnostics and its strategic initiatives, visit Lucid's website.